Nexalin Technology, Inc. announced on April 24, 2025, that its proprietary Gen-2 neurostimulation device received institutional review board (IRB) approval in Brazil. This approval is for a new clinical trial evaluating its use in treating anxiety disorders and chronic insomnia.
The study will be conducted at the Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IPq-HCFMUSP), a prominent psychiatric research institution in Latin America. The first Nexalin device has been shipped to São Paulo, with additional units and single-use disposable electrodes scheduled for delivery.
This Phase II study will enroll 30 adults in São Paulo to assess the efficacy of Nexalin’s non-invasive brain stimulation in reducing anxiety symptoms and improving sleep quality. This marks a key milestone in Nexalin's international strategy, expanding the clinical evaluation of its second-generation neurostimulation technology into an important emerging market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.